InBioGen Co Ltd (101140)

Seoul

Currency in KRW

9,630

+50(+0.52%)

Closed·07:29:59

Fair Value

Unlock Value

Day's Range

9,470

9,900

52 wk Range

4,395

16,570

101140 Income Statement

Featured here, the Income Statement (earnings report) for InBioGen Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Total Revenues

aa.aa

10,217.71

10,480.82

10,419.52

6,240.8

7,041.06

Total Revenues Growth

aa.aa

+4.31%

+2.58%

-0.58%

-40.1%

+12.82%

Cost Of Revenues

aa.aa

9,446.23

8,652.08

8,447.25

4,933.22

6,412.55

Gross Profit

aa.aa

771.48

1,828.74

1,972.28

1,307.58

628.51

Gross Profit Growth

aa.aa

-25.24%

+137.04%

+7.85%

-33.7%

-51.93%

Gross Profit Margin %

aa.aa

7.55%

17.45%

18.93%

20.95%

8.93%

Other Operating Expenses, Total

aa.aa

6,032.36

9,975.21

7,941.62

7,471.36

6,715.37

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+123.33%	+65.36%	-20.39%	-5.92%	-10.12%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	24.6	3.67	8.19	21.89
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5,492.32	8,700.2	6,520.72	5,739.16	5,664.38
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	96.62	158.74	124.04	577.86	59.69

Operating Income

aa.aa

-5,260.88

-8,146.47

-5,969.34

-6,163.78

-6,086.86

Operating Income Growth

aa.aa

-215.19%

-54.85%

+26.72%

-3.26%

+1.25%

EBIT Margin %

aa.aa

-51.49%

-77.73%

-57.29%

-98.77%

-86.45%

Net Interest Expenses

aa.aa

-5,229.01

-1,991.13

-1,863.83

1,026.43

873.55

Net Interest Expenses Growth

aa.aa

-55.34%

+61.92%

+6.39%

+155.07%

-14.89%

Interest Expense, Total

aa.aa

-6,233.11

-3,830.16

-3,686.46

-262.15

-51.35

Interest And Investment Income

aa.aa

1,004.1

1,839.03

1,822.62

1,288.57

924.91

Other Non Operating Expenses, Total

aa.aa

-47,756.76

5,345.68

59,652.19

-21,707.05

22,497.21

EBT, Excl. Unusual Items

aa.aa

-58,246.65

-4,791.92

51,819.02

-26,844.4

17,283.9

Gain (Loss) On Sale Of Assets

aa.aa

-46.1

-138.43

-64.79

-168.16

Other Unusual Items, Total

aa.aa

-1,239.14

-6,745.5

-263.58

-992.37

EBT, Incl. Unusual Items

aa.aa

-45,218.38

111,064.19

-133,902.31

11,858.81

16,122.33

EBT, Incl. Unusual Items Growth

aa.aa

-444.55%

+345.62%

-220.56%

+108.86%

+35.95%

EBT, Incl. Unusual Items Margin

aa.aa

-442.55%

1,059.69%

-1,285.11%

190.02%

228.98%

Income Tax Expense

aa.aa

-140.81

16,939.24

-16,952.89

Net Income to Company

aa.aa

-45,077.57

94,124.95

-117,218.21

11,344.11

16,122.33

Minority Interest

aa.aa

Net Income

aa.aa

-45,077.57

94,124.95

-117,218.21

11,344.11

16,122.33

Net Income Growth

aa.aa

-443.48%

+308.81%

-224.53%

+109.68%

+42.12%

Net Income Margin %

aa.aa

-441.17%

898.07%

-1,124.99%

181.77%

228.98%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-45,077.57

94,124.95

-116,949.42

11,858.81

16,122.33

Basic EPS - Continuing Operations

aa.aa

-21,809.01

35,054.16

-32,253.4

1,393.49

1,614.69

Basic EPS - Continuing Operations Growth

aa.aa

-365.96%

+260.73%

-192.01%

+104.32%

+15.87%

Diluted EPS - Continuing Operations

aa.aa

-21,809.01

31,498.9

-32,253.4

1,393.49

1,614.69

Diluted EPS - Continuing Operations Growth

aa.aa

-467.17%

+244.43%

-202.4%

+104.32%

+15.87%

Basic Weighted Average Shares Outstanding

aa.aa

2.07

2.69

3.63

8.51

9.98

Diluted Weighted Average Shares Outstanding

aa.aa

2.07

2.99

3.63

8.51

9.98

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-4,817.46

-7,029.21

-4,531.27

-4,939.76

-5,029.57

EBITDA Growth

aa.aa

-240.65%

-45.91%

+35.54%

-9.02%

-1.82%

EBITDA Margin %

aa.aa

-47.15%

-67.07%

-43.49%

-79.15%

-71.43%

EBIT

aa.aa

-5,260.88

-8,146.47

-5,969.34

-6,163.78

-6,086.86

* In Millions of KRW (except for per share items)

NSE 30

5,339.18

+30.90

+0.58%

NSE All Share

145,813.86

+1,017.49

+0.70%

US 30

44,193.30

+81.6

+0.18%

US 500

6,344.80

+45.6

+0.72%

FTSE 100

9,164.31

+21.58

+0.24%

DAX

23,904.53

+58.46

+0.25%

South Africa Top 40

92,725.09

+529.59

+0.57%

Market Movers

Name	Last	Chg. %	Vol.
Sterling Bank	8.160	+9.97%	183.77M
Zenith Bank	74.40	-1.98%	60.35M
Access Holdings	27.50	+0.55%	56.24M
UBA	48.10	-1.64%	35.09M
Guaranty Trust Holding	99.40	+0.40%	15.13M
MTN Nigeria	480.00	0.00%	3.82M
Dangote Cement	577.00	0.00%	2.72M

Name	Last	Chg. %	Vol.
Jaiz Bank	4.73	+10.00%	20.48M
Nem	29.700	+10.00%	460.45K
Mutual Benefits Assurance	2.42	+10.00%	19.25M
Guinness Nigeria	128.75	+10.00%	191.23K
Learn Africa	6.270	+10.00%	1.87M
Mansard Ins	12.100	+10.00%	6.74M
SCOA Nigeria	5.500	+10.00%	225.11K

Name	Last	Chg. %	Vol.
UH REIT	57.60	-10.00%	250.19K
Nigerian Exchange	63.00	-10.00%	12.71M
UAC Of Nigeria	90.00	-10.00%	6.94M
Livingtrust Mortgage Bank	5.35	-9.93%	399.81K
Multverse	9.80	-9.68%	565.22K
Rtbriscoe	3.50	-9.09%	947.90K
Initiates	13.00	-7.14%	6.17M

Trending Stocks

Name	Last	Chg. %	Vol.
BUA Cement	183.00	+7.33%	4.14M
Aiico	2.90	+9.85%	90.68M
Initiates	13.00	-7.14%	6.17M
UAC Of Nigeria	90.00	-10.00%	6.94M
Jaiz Bank	4.73	+10.00%	20.48M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa	577.00	+34.83%	777.97
Aaaaaaaaa A Aaaa	68.00	+22.91%	83.58

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

InBioGen Co Ltd (101140)

101140 Income Statement

Trending Stocks